| 109 | 0 | 34 |
| 下载次数 | 被引频次 | 阅读次数 |
目的研究细胞色素P450(CYP)2D6*10多态性对患者手术后应用曲马多止痛后体内曲马多药动学特征的影响。方法 45例患者于手术后首次静脉注射曲马多100 mg,随后采用LC-MS法测定曲马多及其代谢物O-去甲基曲马多(M1)的血浆浓度,采用非房室模型法计算曲马多和M1的主要药动学参数(AUC、CL、t1/2、MRT、ρmax和tmax)。采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术检测患者的CYP2D6*10基因型,即野生型、杂合子和突变型。结果 45例患者中CYP2D6*10等位基因的发生频率为51%。与野生型比较,突变型患者体内曲马多的t1/2、MRT延长,AUC增大,CL减少(P均<0.05)。结论 CYP2D6*10基因多态性对术后患者体内曲马多的药动学特征有显著影响。
Abstract：AIM To investigate the effects of cytochrome P450( CYP) 2D6* 10 on tramadol pharmacokinetic characteristic in post-operative patients who had undergone surgery.METHODS Tramadol was administered to45 post-operative patients,and the plasma concentrations of tramadol and its metabolite O-desmethyltramadol( M1)were subsequently determined by LC-MS method.Pharmacokinetic analyses were performed using non-compartmental methods.The area under the curve( AUC),plasma clearance( CL),elimination half-life( t1 /2),mean residence time( MRT),ρmaxand tmaxof tramadol and M1 were calculated.CYP2D6* 10 was genotyped by polymerase chain reaction-restriction fragment length polymorphism( PCR-RFLP).RESULTS The frequency of CYP2D6* 10 alleles was 51% in the 45 patients.The patients were divided into 3 groups according to their CYP2D6* 10 genotypes: wildtype,heterozygous and homozygous mutant.Pharmacokinetic parameters were compared among the 3 groups.The analyses showed that t1/2,MRT and AUC of tramadol were larger,and CL was lower in homozygous mutant patients compared to the wild-type group( P <0.05).CONCLUSION These results show that the CYP2D6* 10 genetic polymorphism has a significant impact on the pharmacokinetic characteristic of tramadol in post-operative patients.
[1]Pedersen RS,Damkier P,Brsen K.Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers[J].Eur J Clin Pharmacol,2006,62(7):513.
[2]García-Quetglas E,Azanza JR,Sádaba B,et al.Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype[J].Pharmacol Res,2007,55(2):122.
[3]Zhou SF.Polymorphism of human cytochrome P4502D6 and its clinical significance:part II[J].Clin Pharmacokinet,2009,48(12):761.
[4]Frank D,Jaehde U,Fuhr U.Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping[J].Eur J Clin Pharmacol,2007,63(4):321.
[5]盛海辉,肖华胜.细胞色素P450基因多态性与药物代谢[J].国际遗传学杂志,2008,31(3):206.
[6]Neafsey P,Ginsberg G,Hattis D,et al.Genetic polymorphism in cytochrome P450 2D6(CYP2D6):population distribution of CYP2D6activity[J].J Toxicol Environ Health B Crit Rev,2009,12(5):334.
[7]纪玲.快速检测中国人群C2938T、G1846T、G1846A、C188T点突变[J].国际检验医学杂志,2008,29(7):577.
[8]Gan SH,Ismail R,Wan Adnan WA,et al.Correlation of tramadol pharmacokinetics and CYP2D6*10 genotype in Malaysian subjects[J].J Pharm Biomed Anal,2002,30(2):189.
[9]Wang G,Zhang H,He F,et al.Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population[J].Eur J Clin Pharmacol,2006,62(11):927.
[10]Kirchheiner J,Keulen JT,Bauer S,et al.Effects of the CYP2D6gene duplication on the pharmacokinetics and pharmacodynamics of tramadol[J].J Clin Psychopharmacol,2008,28(1):78.
[11]Allegaert K,Anderson BJ,Verbesselt R,et al.Tramadol disposition in the very young:an attempt to assess in vivo cytochrome P-450 2D6 activity[J].Br J Anaesth,2005,95(2):231.
[12]虞建刚,王俊科,李平,等.细胞色素P450 2D6*10基因多态性对曲马多药代动力学的影响[J].中华麻醉学杂志,2008,28(8)677.
[13]李芹,王睿,郭雅,等.中国人群细胞色素P450 2D6基因多态性对曲马多药代动力学的影响[J].中国临床药理学杂志,2009,25(4):302.
[14]Slanar O,Nobilis M,Kvétina J,et al.Pharmacokinetics of tramadol is affected by MDR1 polymorphism C3435T[J].Eur J Clin Pharmacol,2007,63(4):419.
[15]Stamer UM,Musshoff F,Kobilay M,et al.Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6genotypes[J].Clin Pharmacol Ther,2007,82(1):41.
[16]Garcia-BarcelóM,Chow LY,Chiu HF,et al.Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population[J].Clin Chem,2000,46(1):18.
[17]纪玲,潘世秀,吴健民,等.中国大陆人群CYP2D6基因多态性的检测[J].中华医学杂志,2002,115(12):1780.
基本信息:
DOI：10.19577/j.cnki.issn10074406.2014.02.002
中图分类号:R96
引用信息:
[1]吕小琴,张相彩,徐静,等.细胞色素P450 2D6* 10多态性对术后患者体内曲马多药动学特征的影响[J].中国临床药学杂志,2014,23(02):73-77.DOI:10.19577/j.cnki.issn10074406.2014.02.002.
基金信息:
浙江省科技厅资助(编号2010C33120)
2014-03-25
2014-03-25